| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OPRX Stock Overview
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients.
OptimizeRx Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.96 |
| 52 Week High | US$99.18 |
| 52 Week Low | US$21.33 |
| Beta | 0.91 |
| 1 Month Change | 10.20% |
| 3 Month Change | -23.20% |
| 1 Year Change | -53.22% |
| 3 Year Change | 78.66% |
| 5 Year Change | 837.21% |
| Change since IPO | -88.64% |
Recent News & Updates
OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Large and growing TAM with industry tailwinds like digitalization supporting growth in demand for OptimizeRx's solutions. Highly scalable operating model with more than sufficient network capacity to facilitate growth in the near term. OptimizeRx has a strong network of large customers that provides a differentiating factor and competitive advantage to compete against other competitors in the space. The company has a solid balance sheet and has been growing revenue at a rapid pace, setting the stage for near term inflection in profitability. I initiate OptimizeRx with a price target of $48.50, implying 74% upside from current levels.
Shareholder Returns
| OPRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 6.2% | 2.8% | 1.6% |
| 1Y | -53.2% | -39.8% | -20.8% |
Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned -40% over the past year.
Return vs Market: OPRX underperformed the US Market which returned -20.4% over the past year.
Price Volatility
| OPRX volatility | |
|---|---|
| OPRX Average Weekly Movement | 10.0% |
| Healthcare Services Industry Average Movement | 13.1% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: OPRX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 97 | Will Febbo | https://www.optimizerx.com |
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company’s products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products.
OptimizeRx Fundamentals Summary
| OPRX fundamental statistics | |
|---|---|
| Market Cap | US$525.69m |
| Earnings (TTM) | -US$2.75m |
| Revenue (TTM) | US$63.79m |
8.2x
P/S Ratio-191.5x
P/E RatioIs OPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPRX income statement (TTM) | |
|---|---|
| Revenue | US$63.79m |
| Cost of Revenue | US$26.18m |
| Gross Profit | US$37.62m |
| Other Expenses | US$40.36m |
| Earnings | -US$2.75m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 58.96% |
| Net Profit Margin | -4.30% |
| Debt/Equity Ratio | 0% |
How did OPRX perform over the long term?
See historical performance and comparisonValuation
Is OPRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPRX?
Other financial metrics that can be useful for relative valuation.
| What is OPRX's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$525.69m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.9x |
| Enterprise Value/EBITDA | 609.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OPRX's PS Ratio compare to its peers?
| OPRX PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.1x | ||
HCAT Health Catalyst | 3.3x | 16.0% | US$841.0m |
HSTM HealthStream | 2.5x | 8.5% | US$655.1m |
CPSI Computer Programs and Systems | 1.6x | 8.0% | US$462.0m |
BBLN Babylon Holdings | 0.8x | 31.7% | US$413.9m |
OPRX OptimizeRx | 8.2x | 29.8% | US$525.7m |
Price-To-Sales vs Peers: OPRX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the peer average (2.1x).
Price to Earnings Ratio vs Industry
How does OPRX's PE Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: OPRX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the US Healthcare Services industry average (3.3x)
Price to Sales Ratio vs Fair Ratio
What is OPRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.2x |
| Fair PS Ratio | 6.6x |
Price-To-Sales vs Fair Ratio: OPRX is expensive based on its Price-To-Sales Ratio (8.2x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).
Share Price vs Fair Value
What is the Fair Price of OPRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPRX ($28.96) is trading below our estimate of fair value ($171.73)
Significantly Below Fair Value: OPRX is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OPRX's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is OptimizeRx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
157.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OPRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OPRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OPRX's revenue (29.8% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: OPRX's revenue (29.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has OptimizeRx performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-0.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPRX is currently unprofitable.
Growing Profit Margin: OPRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OPRX is unprofitable, and losses have increased over the past 5 years at a rate of 0.4% per year.
Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.7%).
Return on Equity
High ROE: OPRX has a negative Return on Equity (-2.1%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is OptimizeRx's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OPRX's short term assets ($112.7M) exceed its short term liabilities ($6.9M).
Long Term Liabilities: OPRX's short term assets ($112.7M) exceed its long term liabilities ($212.9K).
Debt to Equity History and Analysis
Debt Level: OPRX is debt free.
Reducing Debt: OPRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable OPRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: OPRX is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 12.8% per year.
Discover healthy companies
Dividend
What is OptimizeRx current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OPRX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Will Febbo (52 yo)
6.33yrs
Tenure
US$14,619,576
Compensation
Mr. William J. Febbo, also known as Will, serves as an Independent Director at Augmedix, Inc. since March 28, 2022. He serves as an Independent Director of Modular Medical, Inc. since January 23, 2020. He...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD14.62M) is above average for companies of similar size in the US market ($USD2.81M).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: OPRX's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: OPRX's board of directors are considered experienced (5.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.
Top Shareholders
Company Information
OptimizeRx Corporation's employee growth, exchange listings and data sources
Key Information
- Name: OptimizeRx Corporation
- Ticker: OPRX
- Exchange: NasdaqCM
- Founded: 2006
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$525.692m
- Shares outstanding: 18.15m
- Website: https://www.optimizerx.com
Number of Employees
Location
- OptimizeRx Corporation
- 400 Water Street
- Suite 200
- Rochester
- Michigan
- 48307
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/29 00:00 |
| End of Day Share Price | 2022/06/29 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.